BioSpace News Archive

EXUMA Biotech is developing a new modality to produce CAR cells in a single day, with potentially lower toxicity and higher efficacy without the need for preparative chemotherapies.

Following the decision to limit the coverage of Biogen’s controversial Alzheimer’s drug Aduhelm, the Alzheimer’s community is now waiting for other companies to deliver new therapies.

The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans. Here’s a look at some of the preclinical and early-stage studies recently presented.

Cytovia could become the first company to use a combination of natural killer (NK) cells derived from induced pluripotent stem cell (iPSC) and NK engager antibodies to treat solid tumors.

Some researchers are pointing to the need for an intranasal approach to vaccination in order to block the viral particles from gaining a foothold in the body at the point of entry – the nose.

Turn Bio’s platform is based on using mRNA technology to develop novel medicines to combat age-related diseases.

Curis, a biotech company that develops treatments for cancer, has announced that the FDA has placed a partial clinical hold on its TakeAim lymphoma study.

Surge in prevalence of rare diseases and various life-threatening conditions, preferences for recombinant albumin, and development of cost-effective therapeutics drive the demand for different types of albumin.

TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) ( NCT04504734 ) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammat

Lucira Health, Inc. announced that on April 6, 2022, the Board of Directors of Lucira granted inducement awards consisting of 20,825 restricted stock units to three new employees under Lucira’s 2022 Inducement Plan.